Kidney Stones

Kyle Wood, MD, discusses the different types of hyperoxaluria, the urologist’s role in managing the condition, and the treatments for it.

“While patient facing apps hold great potential to support self-management behaviors, particularly in stone disease, thoughtful consideration across an array of domains should really be taken prior to supporting or even recommending one of these apps to a patient,” says Jared S. Winoker, MD.

"If we can’t get the emergency rooms physicians to apply a bit of common sense to medicine, maybe we should require that they all have a ureteral stent placed for a few weeks during their residency so that they have a better idea of what these patients go through," writes Henry Rosevear, MD.

The study also confirms the growing popularity of ureteroscopy as a stone management tool.

Review of nearly 5600 patients found a 5% pooled incidence of postoperative urosepsis.

Here is what is recommended for fluid intake and dietary changes.

North American urologists analyzing outcomes from their initial experience treating urolithiasis with the high-power super pulse thulium fiber laser (Soltive) are encouraged by the results.

Analyses of data collected in a prospectively maintained database support the recommendation for urologists to consider the minimally invasive version of mini-percutaneous nephrolithotomy for stone removal in patients with medium-sized stones (10-20 mm).

"Everything comes down to patient selection and location of the stones," says one urologist.

The goal of the study is to establish real-world efficacy evidence of using the Soltive Laser System for laser lithotripsy.

Reza Z. Goharderakhshan, MD, discusses how patient compliance for recommended studies increased from less than 10% to 82% following implementation of the program.

Existing evidence does not clarify which patients with acute ureteral colic would benefit most from early surgical intervention.

Experts in prostate cancer, bladder cancer, kidney stones, OAB/incontinence, BPH, and sexual dysfunction recap all the key advances from 2020.

Obesity increases the risk of kidney stone disease, and some weight loss strategies actually increase the risk, according to a recent study.

Investigators have developed a cloud-based, HIPAA–compliant software solution to ensure timely ureteral stent removal and validated its performance in a pilot study.

"Treat the patient as a whole, not just as a stone former," Chew advises.

Quality-of-life data can help guide treatment.

Urologist Henry Rosevear, MD, turns his focus to the topic of evolving approaches to treating stones—and how urologists are compensated for these procedures.

Amy E. Krambeck, MD, discusses the findings of a recent 90-day trial of a single-use disposable ureteroscope.

Holmium laser lithotripsy with Moses 2.0 is intended to enhance precision and versatility by optimizing laser energy transmission.

Super-pulsed thulium fiber laser (TFL) has greater efficiency than a holmium:YAG laser, even when using the TFL with a smaller core-diameter fiber, according to preclinical findings.

The machine learning algorithm incorporates readily available clinical information.

Study results show wide variation in stent placement following ureteroscopy.

Study results show a significant reduction in 24-hour urine oxalate in treated patients.

U.S. academic centers using the Soltive SuperPulsed Laser System to treat stones are finding it offers several advantages compared with holmium:YAG laser lithotripsy. But more research comparing the two is needed, according to a presentation at the 2019 World Congress of Endourology in Abu Dhabi, United Arab Emirates.

Findings from a longitudinal cohort study provide an evidence base for counseling patients about pain and recovery following ureteroscopy for nephrolithiasis.

Providers should incorporate discussion of dietary supplements into patient counseling, Kevin Koo, MD, MPH, MPhil, advises.

Single-access percutaneous nephrolithotomy can clear the vast majority of staghorn stones with minimal morbidity, said Tim Large, MD, at the 2019 World Congress of Endourology and SWL in Abu Dhabi.

Pharmacotherapy for reducing risk of stone recurrence is best reserved for patients with more aggressive disease who are at higher risk for another stone-related event, said Brett A. Johnson, MD, at the 2019 World Congress of Endourology and SWL in Abu Dhabi.

"First... you have to determine if you are in a global period," write Jonathan Rubenstein, MD, and Mark Painter.